SSGJ-617

N/A

Report date: 2024/04/09 17:13:07

Base Information

Drug NameSSGJ-617
Drug Alias Name重组抗PSGL-1单克隆抗体 (Verseau Therapeutics)SSGJ-617SSGJ61761XVTX-0811 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionP-selectin glycoprotein ligand-1 inhibitors
TargetsP-selectin glycoprotein ligand-1
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesVerseau Therapeutics Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesVerseau Therapeutics IncSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A